Onivyde for Metastatic Pancreatic Cancer (Closed)

Details

Generic Name:

Nanoliposomal Irinotecan

Project Status:

Cancelled

Manufacturer:

Baxalta Canada Corporation

Brand Name:

Onivyde

Project Line:

Reimbursement Review

Project Number:

PC0096-000

Tumour Type:

Gastrointestinal

Indications:

Metastatic Pancreatic Cancer

Funding Request:

For second-line treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin in adult patients who have been previously treated with gemcitabine-based therapy

Pre Noc Submission:

Yes

Sponsor:

Baxalta Canada Corporation

Clarification:

The submitter notified pCODR that they will not be filing the submission.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : December 2, 2016